Short-acting β2-agonist prescription patterns for asthma management in the SABINA III primary care cohort

David Price; Kerry  Hancock; Joseph  Doan; Sri Wahyu  Taher; Chakaya J  Muhwa; Hisham  Farouk; Maarten JHI  Beekman

doi:10.1038/s41533-022-00295-7

Short-acting β2-agonist prescription patterns for asthma management in the SABINA III primary care cohort

David Price^* (Corresponding Author), Kerry Hancock, Joseph Doan, Sri Wahyu Taher, Chakaya J Muhwa, Hisham Farouk, Maarten JHI Beekman

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

2 Downloads (Pure)

Abstract

Short-acting β2-agonist (SABA) prescriptions and associated outcomes were assessed in 1,440 patients with asthma from the SABA use IN Asthma (SABINA) III study treated in primary care. Data on asthma medications were collected and multivariable regression models analysed the association of SABA prescriptions with clinical outcomes. Patients (mean age, 47.9 years) were mostly female (68.6%); 58.3% had uncontrolled/partly controlled asthma and 38.8% experienced ≥1 severe exacerbation (reported in 39% of patients with mild asthma). Overall, 44.9% of patients were prescribed ≥3 SABA canisters
(over-prescription) and 21.5% purchased SABA over-the-counter. Higher SABA prescriptions (vs 1−2 canisters) were associated with significantly decreased odds of having at least partly controlled asthma (6–9 and 10–12 canisters) and an increased incidence rate of severe exacerbations (10–12 and ≥13 canisters). Findings revealed a high disease burden, even in patients with ‘mild’ asthma, emphasizing the need for local primary care guidelines based on international recommendations.

Original language	English
Article number	37
Number of pages	10
Journal	npj Primary Care Respiratory Medicine
Volume	32
Early online date	29 Sept 2022
DOIs	https://doi.org/10.1038/s41533-022-00295-7
Publication status	Published - 29 Sept 2022

Bibliographical note

CKNOWLEDGEMENTS
AstraZeneca funded all the SABINA studies and was involved in designing the study, developing the study protocol, conducting the study and performing the analyses. AstraZeneca was given the opportunity to review the manuscript before submission and funded medical writing support. Writing and editorial support was provided in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3) and fully funded by AstraZeneca.

Access to Document

10.1038/s41533-022-00295-7Licence: CC BY

Price_etal_NPJ_Short_Acting_VoR
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Final published version, 594 KBLicence: CC BY

Cite this

@article{aede75d7b2904947b6e95414961dffcf,

title = "Short-acting β2-agonist prescription patterns for asthma management in the SABINA III primary care cohort",

abstract = "Short-acting β2-agonist (SABA) prescriptions and associated outcomes were assessed in 1,440 patients with asthma from the SABA use IN Asthma (SABINA) III study treated in primary care. Data on asthma medications were collected and multivariable regression models analysed the association of SABA prescriptions with clinical outcomes. Patients (mean age, 47.9 years) were mostly female (68.6%); 58.3% had uncontrolled/partly controlled asthma and 38.8% experienced ≥1 severe exacerbation (reported in 39% of patients with mild asthma). Overall, 44.9% of patients were prescribed ≥3 SABA canisters(over-prescription) and 21.5% purchased SABA over-the-counter. Higher SABA prescriptions (vs 1−2 canisters) were associated with significantly decreased odds of having at least partly controlled asthma (6–9 and 10–12 canisters) and an increased incidence rate of severe exacerbations (10–12 and ≥13 canisters). Findings revealed a high disease burden, even in patients with {\textquoteleft}mild{\textquoteright} asthma, emphasizing the need for local primary care guidelines based on international recommendations.",

author = "David Price and Kerry Hancock and Joseph Doan and Taher, {Sri Wahyu} and Muhwa, {Chakaya J} and Hisham Farouk and Beekman, {Maarten JHI}",

note = "CKNOWLEDGEMENTS AstraZeneca funded all the SABINA studies and was involved in designing the study, developing the study protocol, conducting the study and performing the analyses. AstraZeneca was given the opportunity to review the manuscript before submission and funded medical writing support. Writing and editorial support was provided in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3) and fully funded by AstraZeneca. ",

year = "2022",

month = sep,

day = "29",

doi = "10.1038/s41533-022-00295-7",

language = "English",

volume = "32",

journal = "npj Primary Care Respiratory Medicine",

issn = "2055-1010",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Short-acting β2-agonist prescription patterns for asthma management in the SABINA III primary care cohort

AU - Price, David

AU - Hancock, Kerry

AU - Doan, Joseph

AU - Taher, Sri Wahyu

AU - Muhwa, Chakaya J

AU - Farouk, Hisham

AU - Beekman, Maarten JHI

N1 - CKNOWLEDGEMENTS AstraZeneca funded all the SABINA studies and was involved in designing the study, developing the study protocol, conducting the study and performing the analyses. AstraZeneca was given the opportunity to review the manuscript before submission and funded medical writing support. Writing and editorial support was provided in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3) and fully funded by AstraZeneca.

PY - 2022/9/29

Y1 - 2022/9/29

N2 - Short-acting β2-agonist (SABA) prescriptions and associated outcomes were assessed in 1,440 patients with asthma from the SABA use IN Asthma (SABINA) III study treated in primary care. Data on asthma medications were collected and multivariable regression models analysed the association of SABA prescriptions with clinical outcomes. Patients (mean age, 47.9 years) were mostly female (68.6%); 58.3% had uncontrolled/partly controlled asthma and 38.8% experienced ≥1 severe exacerbation (reported in 39% of patients with mild asthma). Overall, 44.9% of patients were prescribed ≥3 SABA canisters(over-prescription) and 21.5% purchased SABA over-the-counter. Higher SABA prescriptions (vs 1−2 canisters) were associated with significantly decreased odds of having at least partly controlled asthma (6–9 and 10–12 canisters) and an increased incidence rate of severe exacerbations (10–12 and ≥13 canisters). Findings revealed a high disease burden, even in patients with ‘mild’ asthma, emphasizing the need for local primary care guidelines based on international recommendations.

AB - Short-acting β2-agonist (SABA) prescriptions and associated outcomes were assessed in 1,440 patients with asthma from the SABA use IN Asthma (SABINA) III study treated in primary care. Data on asthma medications were collected and multivariable regression models analysed the association of SABA prescriptions with clinical outcomes. Patients (mean age, 47.9 years) were mostly female (68.6%); 58.3% had uncontrolled/partly controlled asthma and 38.8% experienced ≥1 severe exacerbation (reported in 39% of patients with mild asthma). Overall, 44.9% of patients were prescribed ≥3 SABA canisters(over-prescription) and 21.5% purchased SABA over-the-counter. Higher SABA prescriptions (vs 1−2 canisters) were associated with significantly decreased odds of having at least partly controlled asthma (6–9 and 10–12 canisters) and an increased incidence rate of severe exacerbations (10–12 and ≥13 canisters). Findings revealed a high disease burden, even in patients with ‘mild’ asthma, emphasizing the need for local primary care guidelines based on international recommendations.

U2 - 10.1038/s41533-022-00295-7

DO - 10.1038/s41533-022-00295-7

M3 - Article

C2 - 36175556

SN - 2055-1010

VL - 32

JO - npj Primary Care Respiratory Medicine

JF - npj Primary Care Respiratory Medicine

M1 - 37

ER -

Short-acting β2-agonist prescription patterns for asthma management in the SABINA III primary care cohort

Abstract

Bibliographical note

Access to Document

Fingerprint

Cite this